Cardiogeni Plc

Developing engineered cellular medicines for regenerative treatment of heart failure.

Aquis Stock Exchange

Overview

Corporate Details

ISIN(s):: GB00BTBLFC12
LEI:: 9845000F8F59ATZD8F92
Country:: United Kingdom
Address:: Celixir House Stratford-Upon-Avon Business & Technology Park, CV37 7GZ Stratford-Upon-Avon
Website:: https://cardiogeni.com/
Sector:: Professional, scientific and technical activities
Industry:: Research and experimental development on natural sciences and engineering

Description

Cardiogeni Plc is a clinical-stage biotechnology company, founded by Nobel Laureate Professor Sir Martin Evans, that focuses on developing next-generation treatments for heart failure. The company specializes in regenerative medicine, utilizing a proprietary platform technology to create engineered cellular medicines. These therapies are designed to treat patients with heart failure, particularly those undergoing coronary artery bypass surgery. Cardiogeni's lead product candidate is CLXR-001. The company's mission is to become a market leader in heart failure regeneration by developing a new class of life-saving treatments.

This is a Fraction of the Available Data.

You're viewing a limited, static snapshot. Professionals use our API to get real-time, AI-ready data for Cardiogeni Plc and 9,000+ other companies.

Stop analyzing yesterday's news. Start building a real-time advantage.

Request Enterprise API Access

Filings

You have of free filing views remaining. Upgrade for unlimited access.

Quick Filters:

Filters

Filing Type

Language

Start date

End date

Clear

Date	Filing	Language	Size
2025-07-24 17:45	Share Issue/Capital Change Details of Advanced Subscription & Company Update	English	21.0 KB
2025-07-24 08:00	Capital/Financing Update £150,000 Advanced Subscription Agreement	English	14.2 KB
2025-07-02 08:00	Regulatory News Service Appointment of corporate broker	English	11.6 KB

Automate Your Workflow. Get a real-time feed of all Cardiogeni Plc filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Cardiogeni Plc via our API.

Get Historical Data →

Insider Transactions

Date	Insider Name	Position	Type	Shares	Value
No insider transactions recorded for this company.

Peer Companies

Company	Country	Ticker
1NKEMIA Offers contract R&D, develops tech platforms, and invests in life sciences ventures.	Spain	IKM
2cureX AB Tests cancer drugs on patient-derived micro-tumors for personalized oncology treatments.	Sweden	2CUREX
4SC AG Developing epigenetic small-molecule drugs for cancers with high unmet medical needs.	Germany	VSC
Abera Bioscience AB Develops next-gen mucosal vaccines using an OMV platform for major infectious diseases.	Sweden	ABERA
ABIVAX Developing oral drugs for chronic inflammatory diseases like ulcerative colitis and Crohn's disease.	France	ABVX
Abliva A clinical-stage biotech developing medicines for rare primary mitochondrial diseases.	Sweden	ABLI
Achiko AG A liquidated health tech firm that developed aptamer diagnostics and a COVID-19 passport app.	Switzerland	ACHI
Acticor Biotech Biopharma developing first-in-class drugs for acute stroke and other thrombotic diseases.	France	ALACT
Active Biotech Develops immunotherapies for cancer and inflammatory diseases with significant unmet needs.	Sweden	ACTI
Addex Therapeutics Ltd Develops oral small molecule drugs, allosteric modulators, for neurological disorders.	Switzerland	ADXN